Nicholas M Snead
Overview
Explore the profile of Nicholas M Snead including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
378
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thi E, Ye X, Snead N, Lee A, Micolochick Steuer H, Ardzinski A, et al.
ACS Infect Dis
. 2024 Sep;
10(10):3640-3649.
PMID: 39306863
Chronic hepatitis B is a global health concern with a high risk of end-stage liver disease. Current standard-of-care agents have low cure rates, and new therapies are needed. Small interfering...
2.
Blake A, Chao J, SantaMaria A, Ekaputri S, Green K, Brown S, et al.
Nat Chem Biol
. 2024 Apr;
20(10):1282-1293.
PMID: 38664586
The natural product hinokitiol mobilizes iron across lipid bilayers at low concentrations and restores hemoglobinization in iron transporter protein-deficient systems. But hinokitiol fails to similarly mobilize iron at higher concentrations,...
3.
Kabra H, Walimbe T, Stuart K, Indey C, Jalgaonkar S, Ikwa E, et al.
Biomaterials
. 2020 Nov;
269:120538.
PMID: 33246740
New therapeutic strategies are needed for the growing unmet clinical needs in liver disease and fibrosis. Platelet activation and PDGF activity are recognized as important therapeutic targets; however, no therapeutic...
4.
Ye X, Tateno C, Thi E, Kakuni M, Snead N, Ishida Y, et al.
ACS Infect Dis
. 2018 Nov;
5(5):738-749.
PMID: 30408957
Hepatitis delta virus (HDV) infects 10-20 million individuals worldwide and causes severe fulminant hepatitis with high likelihood of cirrhosis and hepatocellular carcinoma. HDV infection cannot occur in the absence of...
5.
Thi E, Dhillon A, Ardzinski A, Bidirici-Ertekin L, Cobarrubias K, Cuconati A, et al.
ACS Infect Dis
. 2018 Nov;
5(5):725-737.
PMID: 30403127
Current approved nucleoside analogue treatments for chronic hepatitis B virus (HBV) infection are effective at controlling viral titer but are not curative and have minimal impact on the production of...
6.
Mani N, Cole A, Phelps J, Ardzinski A, Cobarrubias K, Cuconati A, et al.
Antimicrob Agents Chemother
. 2018 Mar;
62(6).
PMID: 29555628
AB-423 is a member of the sulfamoylbenzamide (SBA) class of hepatitis B virus (HBV) capsid inhibitors in phase 1 clinical trials. In cell culture models, AB-423 showed potent inhibition of...
7.
Thi E, Mire C, Lee A, Geisbert J, Zhou J, Agans K, et al.
Nature
. 2015 Apr;
521(7552):362-5.
PMID: 25901685
The current outbreak of Ebola virus in West Africa is unprecedented, causing more cases and fatalities than all previous outbreaks combined, and has yet to be controlled. Several post-exposure interventions...
8.
Snead N, Escamilla-Powers J, Rossi J, McCaffrey A
Mol Ther Nucleic Acids
. 2013 Jul;
2:e103.
PMID: 23820891
Optimization of small interfering RNAs (siRNAs) is important in RNA interference (RNAi)-based therapeutic development. Some specific chemical modifications can control which siRNA strand is selected by the RNA-induced silencing complex...
9.
Snead N, Wu X, Li A, Cui Q, Sakurai K, Burnett J, et al.
Nucleic Acids Res
. 2013 Apr;
41(12):6209-21.
PMID: 23620279
The canonical exogenous trigger of RNA interference (RNAi) in mammals is small interfering RNA (siRNA). One promising application of RNAi is siRNA-based therapeutics, and therefore the optimization of siRNA efficacy...
10.
Snead N, Rossi J
Nucleic Acid Ther
. 2012 Jun;
22(3):139-46.
PMID: 22703279
The manifestation of RNA interference (RNAi)-based therapeutics lies in safe and successful delivery of small interfering RNAs (siRNAs), the molecular entity that triggers and guides sequence-specific degradation of target mRNAs....